Company intelligence / Profile preview

Quodria Ltd

Macclesfield, Cheshire, United Kingdomquodria.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing Q001, a first-in-class topical treatment for atopic dermatitis that targets galectin-3, a protein increased in AD patients' skin. The treatment aims to support skin barrier function while treating localized inflammation.

Therapeutic areas: Dermatology
Modalities: Small moleculesnanotechnology formulations
Industry: Biotech

Drug pipeline

3 assets

Q001

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Galytx Ltd (University of Liverpool spin-out)

Beyond the preview

Go deeper on Quodria Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quodria Ltd.

Explore the full profile